TFX Teleflex Incorporated

Teleflex Publishes 2nd Annual Global JOIN Impact Report

Teleflex Publishes 2nd Annual Global JOIN Impact Report

The annual report highlights how Teleflex is driving the shift towards a sustainable future through its employee-led JOIN Act with Purpose CSR initiative

WAYNE, Pa., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), today announced the publication of its 2nd annual Global JOIN Impact Report. The report outlines the progress the company made in 2019 in the areas of people, environmental sustainability with a focus on pollination, and business programs through its JOIN Act with Purpose initiative. JOIN is Teleflex’s unique way of approaching responsibility powered by its employees.

“I continue to be inspired by the dedication of our employees to act responsibly for the good of our communities, our environment, and those in need. 2019 was no exception,” said Liam Kelly, Chairman, President and CEO. “Our actions across all of Teleflex, including the medical devices we produce, are carried out in support of our Core Values and mission. We also continue to make an impact through the work of The Teleflex Foundation and our Humanitarian Donations Program.”

The theme of ‘Planting with Purpose’ was used across Teleflex’s sites to engage and educate employees about the critical role pollinators play in a sustainable planet. Through volunteering events, employees learned the importance of acting now to improve our conservational efforts and take the necessary steps to ensure we protect our eco-system.

Cam Hicks, Corporate Vice President, Human Resources & Communications said, “Teleflex employees are at the center of everything we do, and because of their efforts, we were able to build on our corporate social responsibility initiatives in 2019. At the local, regional and global levels, thank you for making a difference in the health and quality of people’s lives.”

The Global JOIN Impact Report can be accessed through the home page or investor page of the company’s website .

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit .

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rüsch®, UroLift®, and Weck® – trusted brands united by a common sense of purpose.

Source:

Teleflex Incorporated

Jake Elguicze

Treasurer and Vice President, Investor Relations

610-948-2836

EN
18/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teleflex Incorporated

 PRESS RELEASE

Teleflex Publishes 2024 Global Impact Report

Teleflex Publishes 2024 Global Impact Report Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program WAYNE, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2024 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company’s Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Cl...

 PRESS RELEASE

Teleflex Showcases New Clinical Data Presented at the 2025 American Ur...

Teleflex Showcases New Clinical Data Presented at the 2025 American Urological Association (AUA) Annual Meeting Two Head-to-Head Randomized Trials Highlight Superior Early Patient Experience with the UroLift™ System for BPH1-2 First-Ever Analysis Utilizing the American Urological Association Quality Registry (AQUA) to Assess BPH Treatment Modalities Shows Strongest Symptom Improvement Score Shift with UroLift™ System at Three Months.3 First Study to Confirm Safety of Stabilized Hyaluronic Acid (sHA) Rectal Spacer in Cases with Rectal Wall Infiltration (RWI).4 WAYNE, Pa., May 15, 2025 ...

 PRESS RELEASE

New Retrospective Study Reports Significantly Reduced Post-Operative G...

New Retrospective Study Reports Significantly Reduced Post-Operative GERD Rates with the Titan SGS™ Stapler from Teleflex Compared with Multi-Fire Staplers in Sleeve Gastrectomy Data also demonstrate significantly lower rates of postoperative reflux and decreased incidence of de novo gastroesophageal reflux disease (GERD) without affecting total weight loss at 1-year*, and shorter average hospital length of stay (LOS) associated with use of the Titan SGS™ Stapler compared with multi-fire staplers1 WAYNE, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading g...

 PRESS RELEASE

Teleflex Announces Quarterly Dividend

Teleflex Announces Quarterly Dividend WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 16, 2025, to shareholders of record at the close of business on May 20, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we of...

 PRESS RELEASE

Teleflex Reports First Quarter Financial Results and Full Year 2025 Ou...

Teleflex Reports First Quarter Financial Results and Full Year 2025 Outlook WAYNE, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 30, 2025. First quarter financial summary Revenues of $700.7 million, down 5.0% compared to the prior year period; down 3.8% on an adjusted constant currency basis GAAP diluted EPS from continuing operations of $2.07, compared to $0.33 in the prior year period Adjusted diluted EPS from continuing operations of $2.91, compared to $3.2...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch